Clinical Trials on Coagulation Disorder, Blood

Total 203320 results

Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Von Willebrand Disease

United States, Belgium, Spain, Italy, Turkey, Germany, Austria, France, Czechia, Russian Federation, Ukraine, United Kingdom, Netherlands
Takeda

Completed

A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers

Von Willebrand Disease (VWD)

Canada
Octapharma

Completed

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Von Willebrand Diseases

Lebanon, Croatia, United States, Hungary, Russian Federation, Ukraine, Belarus, Bulgaria
Takeda

Completed

A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

Von Willebrand Disease (VWD)

Germany
Nantes University Hospital

Completed

Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding (PERICOLL)

Von Willebrand Disease

France
Spanish Society of Thrombosis and Haemostasis
Francisco Vidal Pérez; Maria Fernanda López Fernández; Almudena Pérez Rodríguez; Irene Corrales Insa and other collaborators

Unknown

Molecular and Clinical Profile of Von Willebrand Disease in Spain (PCM-EVW-ES)

Von Willebrand Disease

Spain
Postgraduate Institute of Medical Education and...

Recruiting

Heparin Like Effect in Acute Variceal Bleeding

Coagulation Disorder | Cirrhosis, Liver | Variceal Hemorrhage

India
HemoSonics LLC
University Hospital, Lille

Completed

Quantra® System With the QStat® Cartridge in Trauma

Trauma | Coagulation Defect; Bleeding

France
Volkan Deniz, PT

Completed

The Effects of Therapeutic Exercises on Kinesiophobia in Haemophilic Patients.

Haemophilia

Turkey
University of Valencia
Shire

Completed

A Progressive Resistance Training Program in Patients With Haemophilia

Haemophilia

Spain
ANA TORRES-ORTUÑO
Pfizer

Unknown

Adherence to Treatment in Hemophilia (ADHERENCE)

Haemophilia

Spain
Haemnet
UniQure Biopharma B.V.

Completed

An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families (Exigency)

Hemophilia

United Kingdom
HemoSonics LLC

Completed

Coagulation Changes Associated With COVID-19 Infection

Coagulation Disorder | COVID | Disseminated Intravascular Coagulation

United States
Jiangsu Gensciences lnc.

Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A

China
Octapharma

Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

Severe Hemophilia A

Spain, Croatia, Italy, North Macedonia, Serbia
Institute of Hematology & Blood Diseases Hospital...
Sinocelltech Ltd.

Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

China
Wayne State University
Genentech, Inc.

Recruiting

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis (STEP)

Hemophilia A

United States
Prof. Dr. Dr. Thomas Hilberg
Takeda; University of Bonn

Recruiting

Association Between Individual Clotting Factor Level Monitoring and the Risk of Bleeding Whilst Physical Active Conditions (AIM-Active)

Hemophilia A

Germany
Institute of Hematology & Blood Diseases Hospital

Recruiting

Gene Therapy for Chinese Hemophilia A (HA)

Hemophilia A | Gene Therapy

China
Indiana Hemophilia &Thrombosis Center, Inc.
Genentech, Inc.

Recruiting

Hemlibra in Mild Hemophilia A

Factor VIII Deficiency, Congenital

United States
University Hospital, Lille
Groupement Interrégional de Recherche Clinique et d'Innovation

Recruiting

UPLC-MS/MS Monitoring of Emicizumab Therapy (EMICARE)

Hemophilia A

France
Radboud University Medical Center

Active, not recruiting

He-move-philia, Lifestyle Intervention for Patients With Hemophilia

Hemophilia

Netherlands
Cliniques universitaires Saint-Luc- Université...

Completed

Are There Differences Between Carriers of Haemophilia A and B?

Hemophilia

Belgium
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Eradication Trial

Hemophilia A With Inhibitor

United States
Baxalta now part of Shire
Takeda

Completed

RIXUBIS Drug Use-Result Survey (Japan)

Hemophilia B

Japan
Octapharma

Terminated

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria
Children's Hospital Los Angeles
Takeda

Active, not recruiting

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Hemophilia A With Inhibitor

United States
American Thrombosis and Hemostasis Network
Bayer; Shire; CSL Behring; Bioverativ Therapeutics Inc.

Completed

ATHN 2: Factor Switching Study

Hemophilia

United States
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Completed

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (RESIST EXP)

Severe Hemophilia A

United States
Baxalta now part of Shire

Completed

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

Hemophilia A

United States, Spain, Netherlands, Australia, Czechia, Korea, Republic of, Poland, Germany, Taiwan, Israel, Ukraine, United Kingdom, Malaysia, Japan, Austria, Switzerland, Sweden, Bulgaria, Lithuania, Romania
Octapharma

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Severe Hemophilia A

Russian Federation, Ukraine
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Bayer

Terminated

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Hemophilia A and B

Australia, United Kingdom, Taiwan, Japan, Korea, Republic of, Austria, Bulgaria, Hungary, Italy, France, New Zealand
CHU de Reims

Unknown

TFPI Levels in Haemophilia A and B Patients

Haemophilia A and B

France
Boston Children's Hospital
Baxter Healthcare Corporation

Completed

Platelet Function in Patients With Hemophilia A

Hemophilia A

United States
Octapharma

Completed

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Severe Hemophilia A

United States, Bulgaria
Nantes University Hospital

Completed

Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies (ERHEA)

Hemophilia

France
Pfizer

Completed

PF-06741086 Multiple Dose Study in Severe Hemophilia

Hemophilia A or B

United States, Chile, Croatia, Poland, South Africa, Switzerland
Great Ormond Street Hospital for Children NHS Foundation...
University College, London

Completed

What is the Feasibility of the ISTEP Exercise Test in Boys With Haemophilia

Hemophilia

United Kingdom
Margaret Ragni

Withdrawn

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform (INHIBIT)

Severe Hemophilia A

United States
Pfizer

Completed

Registry For Patients Treated With BeneFix In Usual Care Setting In Germany

Hemophilia B

Germany, Austria
Beijing Children's Hospital

Unknown

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China (HA-LD-ITI)

Hemophilia A With Inhibitor

China
Bio Products Laboratory

Completed

A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years

Factor X Deficiency

United Kingdom
Hampshire Hospitals NHS Foundation Trust
Uppsala University; University of Wales Cardiff United Kingdom (UK)

Completed

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

Severe Haemophilia A

United Kingdom
Sahlgrenska University Hospital, Sweden

Completed

Bleeding Symptoms of Carriers of Hemophilia A and B

Hemophilia

Sweden
Hospices Civils de Lyon

Unknown

The Proteins of the Contact Activation System (CONTACT)

Factor XI Deficiency | Factor XII Deficiency

France
University of L'Aquila
TRIB s.r.l.

Completed

Treatment of Inherited Factor VII Deficiency (STER)

Factor VII Deficiency

Italy

Clinical Trials on Coagulation Disorder, Blood

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations